Topics

Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions

22:07 EDT 1 May 2019 | Reuters

The U.S. Food and Drug Administration on Wednesday gave Sanofi SA's dengue vaccine Dengvaxia a very narrow approval as the company continues to suffer from evidence that its vaccine, which took 20 years to develop, can cause severe infections in some...

Original Article: Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions

NEXT ARTICLE

More From BioPortfolio on "Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions"

Quick Search

Relevant Topics

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...